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Vascular endothelial growth factor D (VEGF-D) promotes the lymph nodemetastasis of cancer by inducing the growth of
lymphatic vasculature, but its specific roles in tumorigenesis have not been elucidated. We monitored the effects of
VEGF-D in cutaneous squamous cell carcinoma (cSCC) by subjecting transgenicmice overexpressing VEGF-D in the skin
(K14-mVEGF-D) and VEGF-D knockout mice to a chemical skin carcinogenesis protocol involving 7,12-dimethylben-
z[a]anthracene and 12-O-tetradecanoylphorbol-13-acetate treatments. In K14-mVEGF-Dmice, tumor lymphangiogenesis
was significantly increased and the frequency of lymphnodemetastasiswas elevated in comparisonwith controls.Most
notably, the papillomas regressed more often in K14-mVEGF-D mice than in littermate controls, resulting in a delay in
tumor incidence and a remarkable reduction in the total tumor number. Skin tumor growth and metastasis were not
obviously affected in the absence of VEGF-D; however, the knockout mice showed a trend for reduced
lymphangiogenesis in skin tumors and in the untreated skin. Interestingly, K14-mVEGF-D mice showed an
altered immune response in skin tumors. This consisted of the reduced accumulation of macrophages, mast cells,
and CD4+ T-cells and an increase of cytotoxic CD8+ T-cells. Cytokine profiling by flow cytometry and quantitative
real time PCR revealed that elevated VEGF-D expression results in an attenuated Th2 response and promotes M1/Th1
and Th17 polarization in the early stage of skin carcinogenesis, leading to an anti-tumoral immune environment and the
regression of primary tumors. Our data suggest that VEGF-Dmay be beneficial in early-stage tumors since it suppresses
the pro-tumorigenic inflammation,while at later stagesVEGF-D-induced tumor lymphatics provide a route formetastasis.
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Non-melanoma skin cancer (NMSC) is the most frequent human
cancer worldwide and its incidence is increasing among Caucasian
people due to population aging. Approximately 20% of NMSCs are
cutaneous squamous cell carcinomas (cSCC) and it is the second most
common subtype after basal cell carcinoma. cSCC is mainly caused by
repeated exposure to solar ultraviolet radiation throughout life, but,
for example, chronic ulcers, ionizing radiation, chemicals, papillo-
mavirus infection, and immunosuppressive medication are also risk
factors. Approximately 20% of all the skin cancer related deaths are
caused by metastatic cSCC. The average rate of the nodal metastasis
of cSCC is around 5%, and the five-year survival rate of metastatic
cSCC is less than 35% [1–4]. Metastatic cSCC most often spreads via
tumor-associated lymphatic vessels to sentinel and distant lymph
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other sites of the skin as well as to the lungs, liver, brain, and bone [5].
Increasing experimental and clinical evidence suggests that the
growth of tumor-associated lymphatic vessels, in other words, tumor
lymphangiogenesis, is actively induced in many tumor types [6],
including cSCC [7], and that it promotes early LN metastasis. The
extent of tumor lymphangiogenesis has also been suggested to serve as
an independent predictor of LN metastasis and patient survival [8,9].
Vascular endothelial growth factors (VEGFs) C and D (the
c-fos-induced growth factor [FIGF]) are key stimulators of lymphangio-
genesis. They activate the VEGF receptor 3 (VEGFR-3) that is
constitutively expressed in lymphatic endothelium [10,11]. At least in
part, the signals from VEGFR-3 are transduced via the protein kinase
C-dependent activation of the MEK/ERK1/2 mitogen-activated protein
kinase signaling cascade and induction of Akt1 phosphorylation [12].
VEGFR-3 is expressed also in angiogenic blood vessel endothelia in
tumors and thus signaling through VEGFR-3 can activate tumor
angiogenesis [13]. While VEGF-C is essential for the formation of
lymphatic vasculature during embryonic development [14], VEGF-D is
not [15,16]. Nevertheless, a detailed analysis of dermal lymphatic
network in the Vegfd−/− mice showed that this factor is needed for the
maintenance of caliber and functional capacity of initial lymphatics [17].
In humans, both ligands can also bind to VEGFR-2 on blood vascular
endothelial cells to activate angiogenesis and to support primary tumor
growth and metastasis [18]. In contrast to human VEGF-D, mouse
VEGF-D only binds to VEGFR-3 [19].
High VEGF-C or VEGF-D expression has been shown to boost
VEGFR-3-mediated signaling to promote tumor lymphangiogenesis
and to enhance LN and distant organ metastasis in various
experimental mouse tumor models [20–24]. Conversely, the blocking
of VEGF-C and VEGF-D from binding to VEGFR-3 inhibits these
processes [22,25]. Reduced peritumoral lymphangiogenesis and LN
metastasis have been demonstrated in Vegfd−/− mice in an orthotopic
pancreatic tumor model [16], while the effect of VEGF-C deficiency
on tumor growth is not known so far, due to embryonic lethality of
the constitutive Vegfc deletion. Depending on the experimental
model, human VEGF-D has been observed to either promote [22,24]
or inhibit [23] angiogenesis and tumor growth. In a range of human
cancers, the expression of VEGF-C or VEGF-D positively correlates
with LN metastasis and with poor patient outcome [8,26,27].
Collectively these data indicate that both VEGF-C and VEGF-D may
play major roles in tumor lymphangiogenesis and in metastatic spread
to sentinel and distal LNs and beyond. Targeting these factors and
their downstream signaling pathways could thus be a promising
therapeutic strategy to prevent tumor progression and metastasis.
Although much is known about VEGFs in tumor growth and
metastasis, the specific roles of VEGF-D in cutaneous cancers have not
been studied previously. Here we investigated the effects of VEGF-D on
the development and progression of skin tumors by subjecting both
Vegfd−/− mice [15] and transgenic (TG) mice that overexpress mouse
VEGF-D in the skin (keratin 14 [K14]-mVEGF-D mice) [28] to a
two-stage chemical skin carcinogenesis model [29]. We show that while
Vegfd deletion has rather marginal effects on skin tumor growth and
lymphangiogenesis, TG overexpression of VEGF-D promotes tumor
lymphangiogenesis and metastasis. Interestingly, VEGF-D also induces
significant changes in immune cell and cytokine profiles in the developing
skin tumors, leading to a shift from a protumoral Th2 to antitumoral
Th1/Th17 response, and substantial regression of primary tumors in the
K14-mVEGF-D mice.Materials and Methods
Mice
Age- and sex-matched transgenic K14-mVEGF-D mice overex-
pressing mouse VEGF-D in the skin under the K14 promoter
[Tg(KRT14-Figf)1Ali] [28] in the FVB/N background (TG) and
VEGF-D knockout (KO) (Figf tm1Mach) [15] mice, backcrossed into a
FVB/N (Harlan, the Netherlands) background for at least five
generations, were used for the skin carcinogenesis studies.
Chemical Skin Carcinogenesis
Each experimental group consisted of 15–30 TG, KO or wild type
(WT) littermate control mice of 9–12 weeks of age. Mice were
subjected to the chemical skin carcinogenesis involving
7,12-dimethylbenz[a]anthracene (DMBA; Sigma-Aldrich) and
12-O-tetradecanoyl phorbol-13-acetate (TPA; Sigma-Aldrich) treat-
ments, and tumor development, size and, macroscopic appearance
were monitored once a week for up to 30 weeks, as described earlier
[30]. Mice were sacrificed at weeks 10, 15, 25, and 30, or at
predetermined humane end points (engraved or ulcerative cSCCs,
tumors with a diameter over 10 mm, or excessive tumor load per
mouse). Tumor incidence (the percentage of mice with a tumor) and
cumulative tumor multiplicity (the number of papillomas divided by
the total number of mice alive at the time when the first mouse was
removed from the experiment due to humane end points, as described
by Abel et al. [29]) were recorded. To induce epidermal hyperplasia
and chronic inflammation, the shaved dorsal skin of nine-week old
mice was treated four times, at two-day intervals, with 5 μg of TPA in
acetone and skin samples were collected on the ninth day from the
first application. Mice treated with acetone were used as controls.
Untreated dorsal skin was also collected from nine-week old mice. All
the animal experiments were approved by the Finnish National
Animal Experiment Board.
Tumor and Tissue Sample Harvesting
Mice were sacrificed by CO2 inhalation and cervical dislocation;
skin or skin tumors, and inguinal, axillary, and brachial lymph nodes
were dissected. Tissue samples were either fixed in fresh
phosphate-buffered 4% paraformaldehyde for 24 hours at 4 °C and
embedded in paraffin or snap-frozen in liquid nitrogen.
Hematoxylin-eosin-stained 5 μm sections from the subcapsular
region of LNs were evaluated for the presence of metastases.
Histochemical and Immunohistochemical Analyses
Fixed tissue sections were: treated with trypsin for 30 min at 37 °C
and stained with rat anti-mouse CD-31 antibody (BD Biosciences
PharMingen) or rat anti-mouse VEGF-D antibody (ReliaTech); or
heated in boiling EDTA-Tris buffer (pH 9.0) for 15 minutes and
stained with rat anti-mouse monoclonal F4/80 antibody against
macrophages (Serotec), rat anti-mouse CD45R antibody against
B-lymphocytes (BD Biosciences) or rabbit anti-mouse VEGF-C
antibody (Santa Cruz Biotechnology Inc.); or boiled in 10 mmol/L
citrate buffer (pH 6.0) for 15 minutes and stained with goat
anti-mouse VEGFR-3 antibody (R&D Systems) or rabbit anti-mouse
LYVE-1 antibody [14]. The tyramide signal amplification kit
(Perkin-Elmer) was used according to the manufacturer’s instructions
to intensify color reactions. A biotinylated anti-rat (Vector
Laboratories), anti-rabbit (Jackson Immunoresearch), or anti-goat
(R&D Systems) antibody was used as secondary antibody. A
Histomouse-SP Broad Spectrum (AEC) kit was used to stain helper
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Systems). Killer T-cells, lymphatic vessels and basement membranes
were visualized by immunofluorescence staining using rat anti-mouse
CD8 (R&D Systems), rabbit anti-mouse LYVE-1 [14], and rat
anti-mouse laminin (Chemicon) antibodies, respectively, followed by
appropriate secondary antibodies conjugated with Cy-2 or Cy3
(Jackson Immunoresearch). Cell nuclei were labeled with DAPI
(Sigma-Aldrich). Mast cells were visualized by Leder’s method of
chloroacetate esterase histochemistry [31].
The Quantitation of Vessels and Immune Cells
Intratumoral blood vessels and peritumoral lymphatic vessels were
counted at 200x magnification from 4 to 10 microscopic fields
representing the areas of highest vascular density. Branching
structures were considered as a single vessel. The number of various
inflammatory cell types was counted at 200x magnification from 4 to
6 random fields representing the areas of the highest density of
immune cells within the tissue section. In each time point, 4 to 15
papillomas collected from 3 to 11 individual mice/genotype, and 2 to
10 cSCCs collected from 2 to 10 individual mice/genotype were used
for quantification. Vessels and immune cells in untreated skin (WT =
10, TG = 7) and TPA-treated skin (WT = 6, TG = 6) were counted at
same magnification from 4 to 10 random fields.
Quantitative Real-Time PCR (qPCR)
Total RNA was extracted from untreated skin, TPA-treated skin, and
skin tumors using TriPure reagent (Sigma-Aldrich) according to the
manufacturer’s instructions. In each time point or group, RNAs from at
least 5 samples collected from at least 5 individual mice/genotype were
pooled for qPCR analysis. A total of 0.5μg of RNAwas used to synthesize
cDNA using an iScript cDNA Synthesis Kit (BioRad). The PCR primers
for mouse interleukin (IL)-1β, IL-2, IL-4, IL-6, IL-10, IL-12, IL-17A,
IL-17 F, IL-23p19, interferon (IFN)-γ, transforming growth factor
(TGF)-β, tumor necrosis factor (TNF)-α, and β-actin were obtained
from published studies [32–38]. The primers for the M2 macrophage
marker MRC1/CD206 were 5’-TCGGTGGACTGTGGACGAGCA
(sense) and 5’-TCCCGCCTTTCGTCCTGGCA (antisense), and for
the M1 macrophage marker CD11c/ITGAX 5’-AGCCTTTCT
TCTGCTGTTGGGGT (sense) and 5’-TGTCCGAACTCAG-
CACCGTCCA (antisense). qPCR was performed with iTaq SYBR
Green Supermix with ROX reagents (BioRad). Each sample was run in
duplicate or triplicate using a Mx3005P qPCR device (Stratagene), and
repeated at least three times. Relative RNA levels were calculated by the
2ΔΔCt method [39]. Values were normalized against β-actin, and the
control values (the untreated skin of theWTmice) were expressed as 1 to
indicate a precise fold change.
Fluoresence-Activated Cell Sorting (FACS)
Mouse skin (WT = 6, TG = 5) with emerging papillomas was
removed at week 10 after DMBA and TPA treatments, cut into small
pieces, digested with collagenase (Worthington) for 2–3 h at 37 °C,
washed and resuspended in PBS, and filtered through a 40-μm mesh
to obtain single cell suspension. Cells were first stained for cell-surface
markers, then fixed and permeabilized with Cytofix/Cytoperm (BD
Biosciences) and stained for different intracellular cytokines according
to the manufacturer’s instructions. The following antibodies were
used: fluorescent anti-CD3, CD4, CD8a, CD11b, Ly-6G/C (Gr-1),
F4/80, TNF-α, IFN-γ, IL-4, and IL-6 (all from BD Biosciences).
Isotype-matched antibodies were routinely used for background
correction. Phenotypic populations were defined as follows: CD4+ Thelper cells (CD3+CD4+Gr-1−), CD8+ cytotoxic T-cells (CD3+-
CD8+Gr-1−), and macrophages (Gr-1−CD11b+F4/80+). Samples
were analyzed in duplicate on a FACSCalibur cytometer running
CellQuest software (BD Biosciences). Values reported are given as a
percentage of each immune subpopulation of total cells acquired (for
immune cells) or as mean fluorescence intensity (for cytokines).
Statistical Analysis
For most of the experiments, a two-tailed unpaired t test was used.
When more than two groups were considered (IFN-γ, TNF-α, and
IL-4), a non-parametric Kruskal-Wallis test, followed by a Dunn
post-hoc test, was used. Differences in metastasis formation were
assessed using the χ2 test. In all cases, differences were considered
significant at P b .05, and values are presented as mean ± SD.Results
Skin Tumor Formation is Impaired in K14-mVEGF-D Mice
To explore the in vivo role of VEGF-D in skin carcinogenesis we
first compared the development and progression of chemical-induced
skin tumors between TG K14-mVEGF-D mice and WT control
mice (Figure 1, Supplementary Figure S1; the combined data of two
separate experimental groups is presented in both figures). We
observed a significant delay in tumor incidence (i.e. the proportion of
mice bearing at least one tumor) from week six up to week 13 in the
TG mice in comparison to the controls (P b .01-.001; Figure 1B;
Supplementary Figures S1A and S1C). The delay was the most
prominent in male mice at week seven when only 12% of the TG
males had developed papillomas in comparison with 52% of the WT
males (P b .001) (Figure 1B). Moreover, the TG mice developed
markedly fewer papillomas than the WT mice (Figure 1A and C,
Supplementary Figures S1B and S1D). The differences in papilloma
numbers were already evident at week 7 (P b .01), and from week 13
onwards the TG males showed approximately 40% less papillomas
than the WT males (P b .001). The third experimental group was
followed until week 14, when the rate of tumor development was
comparable to that of the 2 other groups, the TG mice having
significantly less papillomas than the WT mice from week 8 onwards
(P b .05-.001) (not shown). In females tumor multiplicity showed a
similar trend between the genotypes, but the variation between
individuals was greater and statistical significance was reached mainly
at late time points (Supplementary Figure S1B).
Upon tumor monitoring, visual inspection revealed a bigger
proportion of regressing papillomas in the TG mice in comparison
with the controls (P b .05-.001 from week 14 onwards) (Figure 1D).
Differing from typical exophytic pedunculated papillomas of the WT
mice, the appearance of these lesions in the TG mice was sessile, often
slightly scaly, and many of them disappeared gradually (Figure 1A).
Only few regressed-like lesions could be found in the TG mice after
25 weeks, and the skin looked healthy around the remaining and
growing tumors (Figure 1A).
The monitoring of a large number of skin tumors revealed a
difference in tumor size between the TG and WT mice. The
proportion of papillomas over 2 mm in diameter was significantly
lower in the TG mice compared to the WT mice (P b .001 at weeks
10, 15, and 20) (Figure 1E and Supplementary Table S1). Relative to
the controls, the proportion of big tumors (over 6 mm in diameter)
was also clearly lower in the TG mice in the late stages of skin
carcinogenesis (P b .001 at weeks 20 and 25).
Figure 1. Impaired skin tumor formation in TG K14-mVEGF-D mice in a chemical skin carcinogenesis model. Tumors were induced in the
mouse skin using a multistage DMBA-TPA protocol and their growth was monitored for up to 30 weeks (Wk). Data from two separate
experimental groups of males (WT N = 23, TG N = 25) are combined. (A) Representative photographs of the WT and K14-mVEGF-D TG
male mice at different time points. Black arrowheads indicate exophytic papillomas and white arrowheads regressing papillomas. (B)
Tumor incidence showed a significant delay in the TG mice. (C) The TG mice developed markedly less tumors than the WT mice.
Cumulative tumor multiplicity is shown. (D) The percentage of regressing papillomas (the black portion of the column) was higher in the
TG mice (red) than in the WT mice (green). (E) Smaller tumor size in the TG mice than in the WT mice. Tumor sizes are shown as a
percentage of tumors in three different size categories. Statistical significance for each size category is shown in between the column
pairs. (F) At weeks 20–30 the percentage of TG male mice with clinically apparent cSCC was lower than that of WT control males. (G) A
trend towards less cSCCs per mouse was observed in TGmales. N = number of mice. Error bars: SD.*: P b .05; **: P b .01; ***: P b .001;
ns: not significant.
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typically appear as endophytic, often doughnut-shaped tumors with
erosion or ulceration (Supplementary Figure S1E). There was a trend
for lower cSCC incidence in the TG mice than in the WT mice, and
at weeks 23, 24, and 29 this difference was also statistically significant
(P b .05-.01) (Figure 1F). Even though statistically significant
differences were not observed in the cSCC multiplicity between the
genotypes, we found a trend towards less carcinomas per mouse in the
K14-mVEGF-D group than in the control group (Figure 1G).Deletion of Vegfd in mice had no significant effects on skin tumor
growth; nevertheless, the KO males showed a slight trend of more
papillomas and cSCCs per mouse than their WT male littermates
(Figure 2 and Supplementary Figure S2; the combined data of two
separate experimental groups is presented in both figures). Immuno-
histochemistry revealed that in the WT mouse tumors, VEGF-D was
expressed in the stromal compartment by macrophages, and in some
cSCCs also by invasive tumor cells, while sections from the KO
tumors were negative for VEGF-D staining (Figure 2, C and D).
Figure 2.DMBA-TPA-induced skin carcinogenesis in VEGF-D knockout mice. Tumor incidence (A) and cumulative multiplicity (B) in the KO
males (N = 26) and the WT males (N = 27) did not show statistically significant differences between the genotypes. (C-D) Expression of
VEGF-D in mouse skin tumors. Representative immunohistochemical stainings showing VEGF-D expression in mouse cSCCs. (C)
Consecutive sections of the WT cSCC stained with antibodies against VEGF-D and F4/80 demonstrate that VEGF-D is expressed by F4/
80-positive macrophages (arrowheads) within the WT cSCC stroma. Asterisks indicate vessels that facilitate the identification of
co-stained cells in the consecutive sections. (D) VEGF-D expression by invasive carcinoma cells (arrowheads) within theWT cSCC. The KO
cSCC is used as a negative control for VEGF-D staining. (E) The quantification of lymphatic vessel density in the untreated (UT) skin,
TPA-treated skin, and papillomas (PAP) and cSCCs collected at different time points of skin carcinogenesis. The KO tumors showed a
trend for reduced lymphangiogenesis. In the UT skin, and in cSCCs at week 29, the difference between the genotypes was significant. (F)
No significant differences in blood vessel densities between the KO and WT males in any type of sample. Scale bars: 50 μm (C) and 100
μm (D): Error bars: SD. *: P b .05.
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mouse skin markedly impairs tumor development in the chemical
skin carcinogenesis model.
Elevated VEGF-D Leads to an Increase in Tumor
Lymphangiogenesis and in LN Metastasis
VEGF-D acts as a ligand for VEGFR-3, and signaling through this
receptor can activate both tumor lymphangiogenesis and angiogenesis
[18]. The number of peritumoral LYVE-1-positive lymphatic vessels was
significantly higher in the TG mice than in WTmice at various stages of
skin tumorigenesis (papillomas at weeks 10, 15, and 20–24 [P b .05], and
cSCCs at week 30 [P b .05]) (Figure 3A and B; Supplementary Figure
S3). The lymphatic vessel density was also about two times higher in the
untreated TG skin in comparison with the control skin (P b .05), and
strongly increased in the dermis of mutant mice versus controls in
TPA-induced skin hyperplasia (P b .001). In contrast, the papillomas and
cSCCs in the KO mice showed a trend towards decreased tumor
lymphangiogenesis, and in the untreated skin and in cSCCs at week 29,the difference between genotypes was also statistically significant (P b .05)
(Figure 2E). Relative to theWTmice, skin tumor angiogenesis showed no
differences in the TG mice (Figure 3C and D) or KO mice (Figure 2F).
Metastatic dissemination into regional LNs was increased in the
TG mice relative to the WT mice at late time points (Figure 3E) but
not affected in the KO mice (Supplementary Figure S2C). At weeks
26–30 the frequency of LN metastasis in the cSCC-bearing TG mice
was even 60% in comparison with 29% in the WT mice (P b .05;
Figure 3E). These data show that VEGF-D induces lymphangiogen-
esis in mouse skin tumors and promotes tumor metastatic spread at
the late stage of skin carcinogenesis, supporting the previous
observations from other tumor models [22–24].
Altered Immune Response in the Skin Tumors of the
K14-mVEGF-D Mice
In order to explain the distinctly enhanced papilloma regression in
the K14-mVEGF-D mice, we next focused on tumor inflammation.
Immunohistochemical analysis demonstrated markedly less CD4+
Figure 3. Increased tumor lymphangiogenesis and lymph node
metastasis in TG K14-mVEGF-D mice. (A) Representative images of
peritumoral LYVE-1 immunohistochemistry in WT and TG papillomas
atweek 20. (B) The quantification of lymphatic vessel density in the UT
skin, TPA-treated skin, and PAPs and cSCCs collected at different time
points. Tumor lymphangiogenesiswasmoreprominent in the TGmice
than in theWTmice. (C) Representative images of intratumoral CD-31
immunohistochemistry in WT and TG papillomas at week 20. (D) No
significant differences in blood vessel densities between the TG and
WTmice in any type of sample. (E) The frequency of LNmetastasis at
weeks 26–30 was significantly higher in the TG mice than in the WT
mice. Scale bar: 100 μm. Error bars: SD. *: P b .05; ***: P b .001.
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(Figure 4, A and B, and not shown). This difference was already seen
from week 10 onwards and was significant in all stages of skin
carcinogenesis (P b .05 to 0.01). On the contrary, the number ofCD8+ cytotoxic T-cells was prominently increased in TG papillomas
at weeks 20–24 (P b .01) and at week 30 (P b .05) in comparison
with WT papillomas (Figure 4, C and D). We also found a significant
decrease in F4/80+ macrophage accumulation in the TG papillomas
and cSCCs at weeks 20–25 (P b .05–0.01) (Figure 4, E and F), and
also less Leder-positive mast cells in the TG papillomas (a significant
difference at week 30 [P b .05]) (Supplementary Figures S4A and
S4B). FACS analysis corroborated our findings on significantly less
macrophages and CD4+ T-cells, and more CD8+ T-cells at the early
stage of skin tumorigenesis (week 10) (Figure 4G and Supplementary
Figure S5). Immune cells counts were comparable in the untreated
and TPA-treated skin of the TG and WT mice (Figure 4). No
differences were detected in macrophage, mast cell or CD4+ T-cell
counts between the KO and WT tumors nor in the TPA-treated or
untreated skin (Supplementary Figures S4C-S4E).
VEGF-D Modulates Immune Cell Polarization in
Skin Tumors
Depending on microenvironmental signals, macrophages polarize
to either anti-tumoral (M1) or pro-tumoral (M2) phenotypes, and
CD4+ T cells differentiate into various T helper (Th) cell lineages
cells with distinct functions in tumor immunity [40,41]. Simplifying,
the interferon-γ (INF- γ) –producing Th1 subset possesses tumor cell
cytotoxicity and also polarizes macrophages towards M1 phenotype,
while interleukin-4 (IL-4) –producing Th2 cells stimulate alternative
M2 activation program and oppose antitumor responses. Finally, the
roles of IL-17 -producing Th17 subsets in tumors are more complex
and still controversial [40,42].
To evaluate whether VEGF-D production could alter immune
cells polarization during carcinogenesis, we performed qPCR to
compare cytokine levels in total RNA fractions extracted from healthy
skin, TPA-treated skin, and skin tumors collected at different time
points. These data suggested changes in cutaneous cytokine levels
between the TG and WT samples, showing, for example, that the
upregulation of IL-4 mRNA (a typical pro-tumoral cytokine) was
significantly lower in TPA-treated hyperplastic skin and the skin
tumors of the TG mice in comparison to their WT littermates (P b
.05 in papillomas at week 15, and P b .01 in cSCCs at weeks 20–24)
(Figure 5A), possibly indicating a role for VEGF-D in Th1
polarization. Accordingly, the typical M1 biomarkers IL-1β, IL-6,
and IL-12 mRNAs were significantly higher in the untreated TG skin
in comparison with the WT skin (P b .05) (Figure 5B) suggesting the
predisposition of the TG skin towards Th1 responses. During skin
carcinogenesis, however, their expression levels varied depending on
the time point and the genotype (not shown).
As the Th17 cells are known to develop from naïve CD4+ T cells in
the presence of at least IL-6 and IL-1β and are maintained by IL-23
[41,42], we sought to investigate whether the Th1 predisposition of
TG mice would lead to differences in Th17 responses during
experimental skin carcinogenesis. We found that while IL-17A and
IL-17 mRNAs were either undetectable or expressed at very low levels
in all WT samples and in the healthy TG skin, they strongly peaked
in TG papillomas at week 15 (P b .001 for both cytokines), rapidly
dropping down at later stages of papilloma and cSCC development
(Supplementary Figures S6A and S6B). Similarly, IL-23 expression
reached significantly higher levels in TG papillomas at week 15 in
respect to WT papillomas (P b .01), and then decreased to WT
control levels, though with a slower pace than IL-17A and IL-17 F
(Supplementary Figure S6C). No obvious differences were observed
Figure 4. The TGoverexpression of VEGF-D affects inflammatory cell accumulation in skin tumors. Representative photographsof CD4+ (A) and
CD8+ (C) T-cells and F4/80+ macrophages (E) in the peritumoral area ofWT and TG papillomas at week 20. The number of CD4+ (B) and CD8+
T-cells (D), and macrophages (F) in the UT skin, TPA-treated skin, PAPs and cSCCs collected at different time points of skin carcinogenesis.
VEGF-Doverexpression resulted in significantly lessCD4+ T-cells andmacrophages, andmoreCD8+T-cells in skin tumors at several timepoints
of skin carcinogenesis. (G) FACS analysis revealed significantly less CD4+ T-cells (CD3+CD4+Gr-1−) and macrophages (Gr-1−CD11b+F4/80+),
and significantlymoreCD8+ T-cells (CD3+CD8+Gr-1−) in theDMBA-TPA treated skin of the TGmice (N=5) than in theWTmice (N=6) atweek
10 of carcinogenesis. Scale bars: 100 μm (A, E) and 50 μm (C). Error bars: SD. *: P b .05; **: P b .01.
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mRNA levels between the TG and WT mice (not shown).
Altogether, the cytokine expression profiles suggested that experi-
mental overexpression of VEGF-D primes mouse skin towards a
Th1/M1 phenotype, which favors the onset of strong Th17 response
during early phase of tumorigenesis.
To further verify the effects of VEGF-D on the polarization of
immune cells, we quantified key pro- and anti-tumoral cytokines by
intracellular staining and FACS analysis. After 10 weeks of DMBA
and TPA treatments, a significant polarization towards the
production of inflammatory cytokines (TNF-α and IL-6 in
macrophages and TNF-α in T-cells) could be observed in the TG
samples in comparison to the WT samples (Figure 5, C and D;
Supplementary Figure S7), again suggestive of the anti-tumoral M1/
Th1 polarization due to VEGF-D overexpression. Likewise, IFN-γ
(another prototypical Th1 cytokine) was significantly elevated in
T-cells and the macrophages of the TG tumors in comparison withthose of the WT tumors (Figure 5E and Supplementary Figure S7).
Differing from lower total IL-4 mRNA in TG skin relative to WT
skin (Figure 5A), its level was higher in the immune cells of the TG
mice than in those of the WT mice (Figure 5F and Supplementary
Figure S7). Collectively, these data suggest that, in early skin
tumorigenesis, elevated VEGF-D attenuates Th2 polarization in favor
of a more robust Th1 response. This, in turn, could significantly
reduce and delay tumor growth and burden.
Discussion
The most striking observation in this study was the inhibitory effect
of VEGF-D overexpression on primary skin tumor growth. A
comparable finding has been made previously in a Rip1Tag2 mouse
model of pancreatic cancer wherein overexpression of VEGF-D in
β-cells resulted in reduced tumor outgrowth [23]. In our study, the
number and size of the DMBA-TPA-induced skin tumors were
significantly decreased and their incidence delayed in the TG
Figure 5. VEGF-D affects immune cell polarization. Cytokine expression in the skin and skin tumors of the K14-mVEGF-D TGmice andWT
mice. Analyses using qPCR were carried out with total RNA isolated from the UT skin and PAPs collected from the TG mice (white) and
WT mice (black) at different time points during skin tumorigenesis. (A) Interleukin IL-4 mRNA levels were lower in the TG tumors than in
the WT tumors. (B) IL-1β, IL-6 and IL-12 mRNAs were upregulated in the UT TG skin when compared with the UT WT skin. (C-F) FACS
profiling of key cytokines in macrophages and T-cells at week 10 of skin tumorigenesis. Relative to theWTmice (N = 6), the TGmice (N =
5) show a robust Th1 response and polarization towards the M1 phenotype, evidenced by higher levels of anti-tumoral TNF-α (C), IL-6 (D),
and IFN-γ (E), and pro/anti-tumoral IL-4 (D). Error bars: SD. *: P b .05; **: P b .01; ***: P b .001.
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VEGF-C do not appear to affect keratinocyte proliferation or survival
[43], implying that these factors rather have an indirect influence on
primary tumor growth.
Inflammation plays a critical role in tumorigenesis and can either
promote or suppress tumor growth [40,41]. We found that in the
two-stage skin carcinogenesis model, VEGF-D attenuates the Th2
response that normally boosts tumor development via induction of
chronic inflammation. This was evidenced by an increase in the
amount of cytotoxic CD8+ T-cells and a concomitant decrease in
CD4+ T-cells, macrophages, and mast cells in VEGF-D overexpress-
ing tumors. Mice lacking CD4+ T-cells show reduced tumor
incidence and number, and delayed neoplastic progression in
experimental skin cancer, while in the CD8 KO mice, tumor
development is enhanced [44,45]. Moreover, human cSCC patients
with a high amount of peritumoral CD8+ T-cells tend to survive
longer and have a lower neoplastic cell proliferation index [46].FACS analysis of intracellular cytokines in tumor macrophages and
T-cells demonstrated that TNF-α, IFN-γ, and IL-6 were significantly
higher in early stage papillomas of the TG mice rather than the WT
mice, indicating that VEGF-D promotes anti-tumoral M1/Th1
polarization. qPCR revealed high expression of typical Th17 response
markers in early stage TG papillomas relative to WT papillomas, too.
Th17 cells have both pro- and antitumorigenic effects [42], but,
based on our data on significantly less primary skin tumors and
elevated M1/Th1 response in the excess of VEGF-D, we believe the
observed Th17 activation is aimed towards tumor rejection.
However, it should be kept in mind that strict classification of
immune responses to anti-tumoral M1/Th1 and pro-tumoral M2/
Th2 categories simplifies the situation prevailing in tumor tissues, and
immune cells rather show considerable heterogeneity as pointed out
recently for macrophage populations in human cSCC [47].
Unexpectedly, IL-4 was also higher in TG immune cells than in
WT immune cells, but its transcript was constantly lower in the total
444 VEGF-D modulates tumor inflammation and reduces tumor growth Honkanen et al. Neoplasia Vol. 18, No. 7, 2016RNA pool extracted from papillomas and cSCCs. IL-4 is one of the
key pro-tumoral cytokines that supports Th2 activation in an
autocrine manner, induces alternative activation of macrophages, and
downregulates Th1 responses [48]. It should be noted, however, that
IL-4 also has anti-tumoral effects – such as the recruitment and
activation of innate immune cells and the enhancement of CD8+
T-cell mediated anti-tumor immunity – and that its diverse effects in
tumors seem to depend on source and target cells, concentration, and
expression kinetics, as well as on its interaction with multiple
microenvironmental factors [49].
A significant up-regulation of the M1 macrophage markers IL-1β,
IL-6, and IL-12 was also observed in the untreated TG skin in
comparison with the WT skin, while in tumors their levels were
comparable between the genotypes. These observations suggest a selective
skewing of the skin immune environment to favor aM1phenotype in the
untreated TG skin, and a role of VEGF-D in shaping the immune
environment of healthy mouse skin towards an anti-tumoral setup that
preserves the anti-tumoral polarization of tumormacrophages andT-cells,
thus leading the regression of primary tumors in the TG mice.
Interestingly, a recent study showed that VEGF-D induces and a
VEGFR-3 neutralizing antibody suppresses the production of IL-6 by
CD11c+ dendritic cells and results in enhanced anti-tumor immunity in
an allogeneic hematopoietic stem cell transplantationmodel in mice, thus
endorsing our view about the immunomodulative role of the VEGF-D/
VEGFR-3 axis [50]. Moreover, transgenic delivery of VEGF-C or
VEGF-Dwas shown to ameliorate the persistent chronic inflammation in
the oxazolone-treated skin of K14-VEGF-A mice, implying that
functional lymphatic vessels activation via VEGFR-3 functions in
preventing the development of chronic inflammation [51].
The importance of properly regulated VEGFR-3 signaling in
tumor inflammation is further supported by another recent study
wherein the blocking of VEGF-C and VEGF-D by the transgenic
overexpression of soluble VEGFR-3 (sVEGFR-3) inhibited the
development of a pro-tumorigenic tissue microenvironment, leading
to decreased skin tumor growth in the DMBA-TPA model [43].
Consistent with our study, the amounts of macrophages and CD4+
T-cells were significantly lower in the sVEGFR-3 TG skin, however,
changes in macrophage polarization were not observed. Decreases in
CD45+ leukocytes and F4/80+ macrophages, as well as the reduced
growth of pancreatic tumors, were also observed in the Rip1Tag2
model upon VEGF-D overexpression [23], further highlighting
VEGF-D/VEGFR-3 signaling in modulating a tumor immune
environment. The opposite to these findings (an increased number of
macrophages and accelerated tumor growth) was observed in a human
xenograft model upon VEGF-D overexpression [24], but the use of an
immunodeficient host in thismodelmakes it difficult to compare the data
with our immunocompetent model. Hence, both sequestering of
VEGF-C and VEGF-D, and overexpression of VEGF-D appear to
entangle VEGFR-3 signaling in the mouse skin, resulting in an
anti-tumorigenic inflammatorymicroenvironment; however, the detailed
molecular mechanisms behind these observations are still obscure.
Lymphangiogenesis is elevated in various cutaneous tumors and
correlates with the incidence of early sentinel LN metastasis and
reduced survival rates [7,52]. We show here that overexpression of
VEGF-D leads to higher lymphatic vessel densities in healthy mouse
skin, in chronically inflamed skin, and in carcinogen-induced skin
tumors and enhances the spread of cancer cells to sentinel LNs. These
observations are consistent with previous mouse and human data
[16,23,24,26–28]. Interestingly, it was recently shown thatTh17-secreted IL-17 can directly induce VEGF-D expression and
corneal lymphangiogenesis in mice [53]. We observed here both high
IL-17 levels and elevated lymphangiogenesis in early stage skin
tumors of K14-mVEGF-D overexpressing mice. Even if we did not
study the relationship between VEGF-D and IL-17 at molecular
level, the observations by Chauhan et al. and us may imply a crosstalk
between the two growth factors in regulating lymphangiogenesis. In
an opposite result to previous studies [15,16], we detected reduced
lymphatic vessel density in the healthy skin of the Vegfd-deleted mice.
A lack of VEGF-D has been shown to dampen lymphagiogenesis and
metastasis in an orthotopic pancreatic tumor model [16], and we also
found a trend for reduced lymphangiogenesis in the KO papillomas
and cSCCs, albeit with no observed effects on LN metastasis. It
should be noted, however, that the rate of metastasis of experimental
skin tumors is generally low, and also the DMBA-TPA protocol is of
limited utility for studying metastasis [29]. Likewise in human [7],
murine VEGF-D expression was detected in inflammatory cells
adjacent to the cSCC, and in invasive cancer cells, suggesting that it is
up-regulated upon malignant conversion, and contributes to tumor
lymphangiogenesis.
In conclusion, our data imply that aberrant regulation of
VEGFR-3 signaling due to elevated of VEGF-D in the mouse skin
has two outcomes: first, the beneficial modulation of the inflamma-
tory tissue microenvironment, which shifts intratumoral immune
responses away from a tumor-supportive Th2-type and towards a
tumor-suppressive Th1/Th17-type, and substantial regression of
primary skin tumors in an early stage of carcinogenesis; and second,
the prejudicial stimulation of lymphangiogenesis, which raises the
frequency of LN metastasis. While high VEGF-D levels in human
tumors generally correlates positively with increased metastasis and
reduced survival [8,26,27], and with poor differentiation and
increased invasiveness [54,55], correlations with a good prognosis
and high differentiation grade have also been presented recently [56].
Acknowledgments
We thank: Maija Seppänen, Jaana Peters, and Päivi Tuomaala for their
excellent technical assistance, and Dr. Mari Aikio for help with qPCR; Dr.
Steven Stacker and Dr. Marc Achen of the University of Melbourne, for
providing the VEGF-D KO mice for this study; the personnel of the
Laboratory Animal Centre at the University of Oulu and Transgenic Core
Facility at Biocenter Oulu for help with all mouse work; andDr.Markus J.
Mäkinen and Riitta Vuento of the Department of Pathology of the
University of Oulu, for help with the immunohistochemical staining and
analysis.
Appendix A. Supplementary data
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.neo.2016.05.002.
References
[1] Alam M and Ratner D (2001). Cutaneous squamous-cell carcinoma. N Engl J
Med 344, 975–983.
[2] Kivisaari A and Kähäri VM (2013). Squamous cell carcinoma of the skin:
emerging need for novel biomarkers. World J Clin Oncol 4, 85–90. http:
//dx.doi.org/10.5306/wjco.v4.i4.85.
[3] Madan V, Lear JT, and Szeimies RM (2010). Non-melanoma skin cancer. Lancet
375, 673–685. http://dx.doi.org/10.1016/S0140-6736(09)61196-X.
[4] Fu J, Bassi DE, Zhang J, Li T, Cai KQ, Testa CL, Nicolas E, and Klein-Szanto
AJ (2013). Enhanced UV-induced skin carcinogenesis in transgenic mice
overexpressing proprotein convertases. Neoplasia 15, 169–179.
Neoplasia Vol. 18, No. 7, 2016 VEGF-D modulates tumor inflammation and reduces tumor growth Honkanen et al. 445[5] Weinberg AS, Ogle CA, and Shim EK (2007). Metastatic cutaneous squamous
cell carcinoma: an update. Dermatol Surg 33, 885–899.
[6] Edge SB and Compton CC (2010). The American Joint Committee on Cancer:
the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann
Surg Oncol 17, 1471–1474. http://dx.doi.org/10.1245/s10434-010-0985-4.
[7] Moussai D, Mitsui H, Pettersen JS, Pierson KC, Shah KR, Suárez-Fariñas M,
Cardinale IR, Bluth MJ, Krueger JG, and Carucci JA (2011). The human cutaneous
squamous cell carcinoma microenv ironment is characterized by increased lymphatic
density and enhanced expression of macrophage-derived VEGF-C. J Invest Dermatol
131, 229–236. http://dx.doi.org/10.1038/jid.2010.266.
[8] Tobler NE and Detmar M (2006). Tumor and lymph node lymphangiogenesis -
impact on cancer metastasis. J Leukoc Biol 80, 691–696.
[9] Ruddell A, Harrell MI, Furuya M, Kirschbaum SB, and Iritani BM (2011). B
lymphocytes promote lymphogenous metastasis of lymphoma and melanoma.
Neoplasia 13, 748–757.
[10] Joukov V, Pajusola K, Kaipainen A, Chilov D, Lahtinen I, Kukk E, Saksela O,
Kalkkinen N, and Alitalo K (1996). A novel vascular endothelial growth factor,
VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor
tyrosine kinases. EMBO J 15, 290–298.
[11] Achen MG, Jeltsch M, Kukk E, Mäkinen T, Vitali A, Wilks AF, Alitalo K, and
Stacker SA (1998). Vascular endothelial growth factor D (VEGF-D) is a ligand
for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4).
Proc Natl Acad Sci U S A 95, 548–553.
[12] Mäkinen T, Veikkola T, Mustjoki S, Karpanen T, Catimel B, Nice EC, Wise L,
Mercer A, Kowalski H, and Kerjaschki D, et al (2001). Isolated lymphatic
endothelial cells transduce growth, survival and migratory signals via the
VEGF-C/D receptor VEGFR-3. EMBO J 20, 4762–4773.
[13] Tammela T, Zarkada G, Wallgard E, Murtomäki A, Suchting S, Wirzenius M,
Waltari M, Hellström M, Schomber T, and Peltonen R, et al (2008). Blocking
VEGFR-3 suppresses angiogenic sprouting and vascular network formation.
Nature 454, 656–660. http://dx.doi.org/10.1038/nature07083.
[14] Kärkkäinen MJ, Haiko P, Sainio K, Partanen J, Taipale J, Petrova TV, Jeltsch M,
Jackson DG, Talikka M, and Rauvala H, et al (2004). Vascular endothelial
growth factor C is required for sprouting of the first lymphatic vessels from
embryonic veins. Nat Immunol 5, 74–80.
[15] Baldwin ME, Halford MM, Roufail S, Williams RA, Hibbs ML, Grail D, Kubo
H, Stacker SA, and Achen MG (2005). Vascular endothelial growth factor D is
dispensable for development of the lymphatic system. Mol Cell Biol 25,
2441–2449.
[16] KochM,DettoriD,VanNuffelenA, Souffreau J,Marconcini L,WallaysG,Moons L,
Bruyère F, Oliviero S, and Noel A, et al (2009). VEGF-D deficiency in mice does not
affect embryonic or postnatal lymphangiogenesis but reduces lymphatic metastasis. J
Pathol 219, 356–364. http://dx.doi.org/10.1002/path.2605.
[17] Paquet-Fifield S, Levy SM, Sato T, Shayan R, Karnezis T, Davydova N, Nowell
CJ, Roufail S, Ma GZ, and Zhang YF, et al (2013). Vascular endothelial growth
factor-d modulates caliber and function of initial lymphatics in the dermis. J
Invest Dermatol 133, 2074–2084. http://dx.doi.org/10.1038/jid.2013.83.
[18] Alitalo K (2011). The lymphatic vasculature in disease.Nat Med 17, 1371–1380.
http://dx.doi.org/10.1038/nm.2545.
[19] Baldwin ME, Catimel B, Nice EC, Nice EC, Roufail S, Hall NE, Stenvers KL,
Kärkkainen MJ, Alitalo K, and Stacker SA, et al (2001). The specificity of
receptor binding by vascular endothelial growth factor-d is different in mouse and
man. J Biol Chem 276, 19166–19171.
[20] Mandriota SJ, Jussila L, Jeltsch M, Compagni A, Baetens D, Prevo R, Banerji S,
Huarte J, Montesano R, and Jackson DG, et al (2001). Vascular endothelial
growth factor-C-mediated lymphangiogenesis promotes tumour metastasis.
EMBO J 20, 672–682.
[21] Skobe M, Hawighorst T, Jackson DG, Prevo R, Janes L, Velasco P, Riccardi L,
Alitalo K, Claffey K, and Detmar M (2001). Induction of tumor lymphangio-
genesis by VEGF-C promotes breast cancer metastasis. Nat Med 7, 192–198.
[22] Stacker SA, Caesar C, Baldwin ME, Thornton GE, Williams RA, Prevo R,
Jackson DG, Nishikawa S, Kubo H, and Achen MG (2001). VEGF-D
promotes the metastatic spread of tumor cells via the lymphatics. Nat Med 7,
186–191.
[23] Kopfstein L, Veikkola T, Djonov VG, Baeriswyl V, Schomber T, Strittmatter K,
Stacker SA, Achen MG, Alitalo K, and Christofori G (2007). Distinct roles of
vascular endothelial growth factor-D in lymphangiogenesis and metastasis. Am J
Pathol 170, 1348–1361.
[24] Harris NC, Paavonen K, Davydova N, Roufail S, Sato T, Zhang YF, Karnezis T,
Stacker SA, and Achen MG (2011). Proteolytic processing of vascular endothelialgrowth factor-D is essential for its capacity to promote the growth and spread of
cancer. FASEB J 25, 2615–2625. http://dx.doi.org/10.1096/fj.10-179788.
[25] He Y, Kozaki K, Karpanen T, Koshikawa K, Ylä-Herttuala S, Takahashi T, and
Alitalo K (2002). Suppression of tumor lymphangiogenesis and lymph node
metastasis by blocking vascular endothelial growth factor receptor 3 signaling. J
Natl Cancer Inst 94, 819–825.
[26] Stacker SA, Williams RA, and Achen MG (2004). Lymphangiogenic growth
factors as markers of tumor metastasis. APMIS 112, 539–549.
[27] Achen MG, McColl BK, and Stacker SA (2005). Focus on lymphangiogenesis in
tumor metastasis. Cancer Cell 7, 121–127.
[28] Haiko P, Mäkinen T, Keskitalo S, Taipale J, Kärkkainen MJ, Baldwin ME, Stacker
SA, AchenMG, andAlitalo K (2008).Deletion of vascular endothelial growth factor C
(VEGF-C) and VEGF-D is not equivalent to VEGF receptor 3 deletion in mouse
embryos.Mol Cell Biol 28, 4843–4850. http://dx.doi.org/10.1128/MCB.02214-07.
[29] Abel EL, Angel JM, Kiguchi K, and DiGiovanni J (2009). Multi-stage chemical
carcinogenesis in mouse skin: fundamentals and applications. Nat Protoc 4,
1350–1362. http://dx.doi.org/10.1038/nprot.2009.120.
[30] Brideau G,MäkinenMJ, Elamaa H, Tu H, Nilsson G, Alitalo K, Pihlajaniemi T,
and Heljasvaara R (2007). Endostatin overexpression inhibits lymphangiogenesis
and lymph node metastasis in mice. Cancer Res 67, 11528–11535.
[31] Leder LD (1979). The chloroacetate esterase reaction. A useful means of
histological diagnosis of hematological disorders from paraffin sections of skin.
Am J Dermatopathol 1, 39–42.
[32] Garaczi E, Széll M, Jánossy T, Koreck A, Pivarcsi A, Buzás E, Pos Z, Falus A,
Dobozy A, and Kemény L (2004). Negative regulatory effect of histamine in
DNFB-induced contact hypersensitivity. Int Immunol 16, 1781–1788.
[33] Kar Mahapatra S, Bhattacharjee S, Chakraborty SP, Majumdar S, and Roy S (2011).
Alteration of immune functions and Th1/Th2 cytokine balance in nicotine-induced
murine macrophages: immunomodulatory role of eugenol and N-acetylcysteine. Int
Immunopharmacol 11, 485–495. http://dx.doi.org/10.1016/j.intimp.2010.12.020.
[34] Stober CB, Lange UG, Roberts MT, Alcami A, and Blackwell JM (2005). IL-10
from regulatory T cells determines vaccine efficacy in murine Leishmania major
infection. J Immunol 175, 2517–2524.
[35] Udalov S, Dumitrascu R, Pullamsetti S, Al-tamari HM,WeissmannN,GhofraniHA,
Guenther A, Voswinckel R, Seeger W, and Grimminger F, et al (2010). Effects of
phosphodiesterase 4 inhibition on bleomycin-induced pulmonary fibrosis in mice.
BMC Pulm Med 10, 26. http://dx.doi.org/10.1186/1471-2466-10-26.
[36] YangXO,Chang SH, ParkH,Nurieva R, ShahB,Acero L,Wang Y-H, Schluns KS,
Broaddus RR, and Zhu Z, et al (2008). Regulation of inflammatory responses by
IL-17 F. J Exp Med 205, 1063–1075. http://dx.doi.org/10.1084/jem.20071978.
[37] Smith E, StarkMA, ZarbockA, Burcin TL, Bruce AC, VaswaniD, Foley P, and Ley
K (2008). IL-17A inhibits the expansion of IL-17A-producing T cells in mice
through “short-loop” inhibition via IL-17 receptor. J Immunol 181, 1357–1364.
[38] Kapil P, Atkinson R, Ramakrishna C, Cua DJ, Bergmann CC, and Stohlman SA
(2009). Interleukin-12 (IL-12), but not IL-23, deficiency ameliorates viral
encephalitis without affecting viral control. J Virol 83, 5978–5986. http:
//dx.doi.org/10.1128/JVI.00315-09.
[39] Livak KJ and Schmittgen TD (2001). Analysis of relative gene expression data
using real-time quantitative PCR and the 2(−Delta Delta C(T)) method.Methods
25, 402–408.
[40] Sica A, Larghi P,Mancino A, Rubino L, Porta C, TotaroMG, RimoldiM, Biswas SK,
Allavena P, andMantovani A (2008).Macrophage polarization in tumour progression.
SeminCancer Biol 18, 349–355. http://dx.doi.org/10.1016/j.semcancer.2008.03.004.
[41] Zhu J, Yamane H, and Paul WE (2010). Differentiation of effector
CD4 T cell populations. Annu Rev Immunol 28, 445–489. http:
//dx.doi.org/10.1146/annurev-immunol-030409-101212.
[42] Bailey SR, Nelson MH, Himes R, Li Z, Mehrotra S, and Paulos CM (2014).
Th17 cells in cancer: the ultimate identity crisis. Front Immunol 5, 276.
http://dx.doi.org/10.3389/fimmu.2014.00276.
[43] Alitalo AK, Proulx ST, Karaman S, Karaman S, Aebischer D, Martino S, Jost M,
Schneider N, Bry M, and Detmar M (2013). VEGF-C and VEGF-D Blockade
Inhibits Inflammatory Skin Carcinogenesis. Cancer Res 73, 4212–4221.
http://dx.doi.org/10.1158/0008-5472.CAN-12-4539.
[44] Yusuf N, Nasti TH, Katiyar SK, Jacobs MK, Seibert MD, Ginsburg AC, Timares
L, Xu H, and Elmets CA (2008). Antagonistic roles of CD4+ and CD8+ T-cells
in 7,12-dimethylbenz[a]anthracene cutaneous carcinogenesis. Cancer Res 68,
3924–3930. http://dx.doi.org/10.1158/0008-5472.CAN-07-3059.
[45] Daniel D, Meyer-Morse N, Bergsland EK, Dehne K, Coussens LM, and
Hanahan D (2003). Immune enhancement of skin carcinogenesis by CD4+ T
cells. J Exp Med 197, 1017–1028.
446 VEGF-D modulates tumor inflammation and reduces tumor growth Honkanen et al. Neoplasia Vol. 18, No. 7, 2016[46] Zancope E, Costa NL, Junqueira-Kipnis AP, Valadares MC, Silva TA, Leles CR,
Mendonça EF, and Batista AC (2010). Differential infiltration of CD8+ and NK
cells in lip and oral cavity squamous cell carcinoma. J Oral Pathol Med 39,
162–167. http://dx.doi.org/10.1111/j.1600-0714.2009.00792.x.
[47] Pettersen JS, Fuentes-Duculan J, Suárez-Fariñas M, Pierson KC, Pitts-Kiefer A,
Fan L, Belkin DA, Wang CQ, Bhuvanendran S, and Johnson-Huang LM, et al
(2011). Lowes MA, Carucci JA. Tumor-associated macrophages in the cutaneous
SCC microenvironment are heterogeneously activated. J Invest Dermatol 131,
1322–1330. http://dx.doi.org/10.103/jid.2011.9.
[48] Gabrilovich DI, Ostrand-Rosenberg S, and Bronte V (2012). Coordinated
regulation of myeloid cells by tumours. Nat Rev Immunol 12, 253–268.
http://dx.doi.org/10.1038/nri3175.
[49] Wang H-W and Joyce JA (2010). Alternative activation of tumor-associated
macrophages by IL-4. Cell Cycle 9, 4824–4835.
[50] Udagawa T, Narumi K, Suzuki K, Aida K, Miyakawa R, Ikarashi Y, Makimoto
A, Chikaraishi T, Yoshida T, and Aoki K (2013). Vascular endothelial growth
factor-D-mediated blockade of regulatory T cells within tumors is induced
by hematopoietic stem cell transplantation. J Immunol 191, 3440–3452.
http://dx.doi.org/10.4049/jimmunol.1201454.[51] Huggenberger R,Ullmann S, Proulx ST, Pytowski B, AlitaloK, andDetmarM (2010).
Stimulation of lymphangiogenesis via VEGFR-3 inhibits chronic skin inflammation. J
Exp Med 207, 2255–2269. http://dx.doi.org/10.1084/jem.20100559.
[52] Rinderknecht M and Detmar M (2008). Tumor lymphangiogenesis and melanoma
metastasis. J Cell Physiol 216, 347–354. http://dx.doi.org/10.1002/jcp.21494.
[53] Chauhan SK, Jin Y, Goyal S, Lee HS, Fuchsluger TA, Lee HK, and Dana R
(2011). A novel pro-lymphangiogenic function for Th17/IL-17. Blood 118,
4630–4634. http://dx.doi.org/10.1182/blood-2011-01-332049.
[54] KozlowskiM,KowalczukO,MilewskiR,ChyczewskiL,Niklinski J, andLaudanski J (2010).
Serum vascular endothelial growth factors C andD in patients with oesophageal cancer. Eur J
Cardiothorac Surg 38, 260–267. http://dx.doi.org/10.1016/j.ejcts.2010.01.061.
[55] Sotiropoulou N, Bravou V, Kounelis S, Damaskou V, Papaspirou E, and
Papadaki H (2010). Tumour expression of lymphangiogenic growth factors but
not lymphatic vessel density is implicated in human cervical cancer progression.
Pathology 42, 629–636. http://dx.doi.org/10.3109/00313025.2010.522174.
[56] Szajewski M, Kruszewski WJ, Lakomy J, Ciesielski M, Kawecki K, Jankun J,
Buczek T, and Szefel J (2014). VEGF-C and VEGF-D overexpression is more
common in left-sided and well-differentiated colon adenocarcinoma. Oncol Rep
31, 125–130. http://dx.doi.org/10.3892/or.2013.2821.
